Marginal zone lymphoma of the colon: case series from a single center and SEER data review

Abstract

Colon extranodal marginal zone lymphoma (EMZL) is poorly characterized in the literature. We performed a retrospective review of patients with colon EMZL at our institution and from the Surveillance Epidemiology and End Results (SEER) database. Eight patients were identified in our institution with majority (88%) presenting with stage-I disease. Initial management included active surveillance, polypectomy followed by surveillance, and surgical resection followed by chemotherapy. One patient with concurrent prostate carcinoma received radiation to the rectum. Initial therapy led to complete remission in five out of six treated patients with four of them maintaining remission at 88 months. SEER database identified 361 patients with stage-I colon EMZL. Overall survival for this cohort was 73.9% at 10 years with no significant difference in outcomes between treatment groups. Our single institution experience and the SEER data analysis emphasize indolent nature of colon EMZL and need for non-aggressive therapeutic approaches.

Keywords:

• Colon marginal zone lymphoma
• colonic lymphoma
• extranodal marginal zone lymphoma

Acknowledgments

ISL is supported by grant 1R01CA233945 from the National Cancer Institute (NCI), the Intramural Funding Program from the University of Miami SCCC, by the Dwoskin and Anthony Rizzo Families Foundations, and Jaime Erin Follicular Lymphoma Research Consortium. Research reported in this publication was also supported by the NCI of the NIH under award number P30CA240139.

Disclosure statement

A.T, and J.F, G.R, E.S, S.I, J.R.C, J.P, D.A.S declare no conflict of interest. J.P.A. has received honoraria from OncLive and Oncinfo and has served on the advisory board of ADC Therapeutics. An immediate family member has served on the advisory boards of Puma Biotechnology, Inovio Pharmaceuticals, Agios Pharmaceuticals, Forma Therapeutics, and Foundation Medicine. I.S.L. has served on the advisory boards of Seattle Genetics, Janssen Scientific, Karyopharm Therapeutics and Verastem.

Data availability statement

Data available through the Surveillance Epidemiology and End Results (SEER) database

Additional information

Funding

No funding was used for this project.